CR20170355A - Composición probiótica que comprende al menos bifidobacterium bifidum w23 y es capaz de controlar la función de la barrera intestinal - Google Patents

Composición probiótica que comprende al menos bifidobacterium bifidum w23 y es capaz de controlar la función de la barrera intestinal

Info

Publication number
CR20170355A
CR20170355A CR20170355A CR20170355A CR20170355A CR 20170355 A CR20170355 A CR 20170355A CR 20170355 A CR20170355 A CR 20170355A CR 20170355 A CR20170355 A CR 20170355A CR 20170355 A CR20170355 A CR 20170355A
Authority
CR
Costa Rica
Prior art keywords
function
control
bifidobacterium bifidum
probiotic composition
intestinal barrier
Prior art date
Application number
CR20170355A
Other languages
English (en)
Inventor
Hemert Saskia Van
Original Assignee
Winclove Holding B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Winclove Holding B V filed Critical Winclove Holding B V
Publication of CR20170355A publication Critical patent/CR20170355A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/517—Bifidum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La invención se refiere al campo de la medicina y la nutrición, más específicamente al campo del tratamiento y prevención de trastornos humanos tales como depresión, rumiación, agresión, migraña, trastornos del espectro autista (incluyendo autismo y TDAH), esquizofrenia, síndrome metabólico o diabetes tipo II
CR20170355A 2015-02-03 2016-02-03 Composición probiótica que comprende al menos bifidobacterium bifidum w23 y es capaz de controlar la función de la barrera intestinal CR20170355A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15153724 2015-02-03
PCT/EP2016/052285 WO2016124642A1 (en) 2015-02-03 2016-02-03 Probiotic composition at least comprising bifidobacterium bifidum w23 and capable of controlling intestinal barrier function

Publications (1)

Publication Number Publication Date
CR20170355A true CR20170355A (es) 2018-02-20

Family

ID=52477560

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170355A CR20170355A (es) 2015-02-03 2016-02-03 Composición probiótica que comprende al menos bifidobacterium bifidum w23 y es capaz de controlar la función de la barrera intestinal

Country Status (9)

Country Link
US (1) US20180271919A1 (es)
EP (1) EP3253397A1 (es)
KR (1) KR20170129718A (es)
CN (1) CN107427539A (es)
AU (1) AU2016214420B2 (es)
CA (1) CA2975553A1 (es)
CR (1) CR20170355A (es)
EC (1) ECSP17053244A (es)
WO (1) WO2016124642A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180019474A (ko) * 2016-08-16 2018-02-26 주식회사 엠디헬스케어 락토바실러스 플란타룸 유래 소포를 포함하는 정신질환 예방 또는 치료용 조성물
US10428370B2 (en) 2016-09-15 2019-10-01 Sun Genomics, Inc. Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample
US11959125B2 (en) 2016-09-15 2024-04-16 Sun Genomics, Inc. Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample
CN107586736A (zh) * 2017-05-05 2018-01-16 南昌大学 两歧双歧杆菌m2017063及其在缓解慢性肾脏疾病药物的应用
CN107699517A (zh) * 2017-10-17 2018-02-16 无限极（中国）有限公司 一种青春双歧杆菌及其用途
KR102100122B1 (ko) * 2017-12-15 2020-04-13 (주)녹십자웰빙 신장 질환 예방용 건강기능성 식품 조성물 및 프로바이오틱스
CN108079023B (zh) * 2018-01-04 2020-10-09 诺佰克（武汉）生物科技有限公司 马乳酒样乳杆菌zw3在制备预防或改善应激压力引发精神问题的药物中的应用
JPWO2019188943A1 (ja) * 2018-03-26 2021-03-25 森永乳業株式会社 脳血流低下の予防及び／又は改善用組成物
WO2019202033A1 (en) * 2018-04-18 2019-10-24 Danstar Ferment Ag Method for alleviating tobacco or nicotine withdrawal symptoms
WO2020037533A1 (zh) * 2018-08-22 2020-02-27 江南大学 长双歧杆菌婴儿亚种ccfm687、其发酵食品及其应用
CN109182207B (zh) * 2018-10-10 2020-10-27 北京首佳利华科技有限公司 一株具有调节血糖和胆固醇水平等益生功能的嗜酸乳杆菌La-SJLH001及其应用
CA3116010A1 (en) * 2018-10-26 2020-04-30 Sun Genomics Inc. Universal method for extracting nucleic acid molecules from a diverse population of microbes
WO2020157297A1 (en) * 2019-02-01 2020-08-06 Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement Lactococcus lactis strains for the prevention and/or the treatment of visceral pain
KR102148707B1 (ko) * 2019-02-22 2020-08-31 한국식품연구원 우울증 및 불안장애의 예방, 개선 또는 치료 효능을 갖는 김치 유산균 락토바실러스 사케아이
WO2020250185A1 (en) * 2019-06-12 2020-12-17 Glycom A/S Human milk oligosaccharides and compositions thereof for use in preventing, managing or treating symptoms related to migraine
KR20200145941A (ko) 2019-06-21 2020-12-31 주식회사한국야쿠르트 락토바실러스 카제이 hy2782를 유효성분으로 함유하는 미세먼지에 의한 밀착연접단백질 관련 질환의 예방 또는 개선용 식품조성물
IT201900011193A1 (it) * 2019-07-08 2021-01-08 Sofar Spa Ceppo di batteri Bifidobacterium bifidum, sue composizioni e relativi usi
CN111073828B (zh) * 2019-11-19 2022-04-15 江南大学 一种长双歧杆菌长亚种及其应用
CN112914107B (zh) * 2020-11-05 2022-08-02 温州大学 一株用于治疗抑郁的益生菌株Ls17及其应用
CN112458016B (zh) * 2020-11-27 2021-11-19 石家庄君乐宝乳业有限公司 两歧双歧杆菌i771、其分离纯化方法及应用
KR102215599B1 (ko) 2020-12-28 2021-02-15 주식회사 에이치이엠 신규한 비피도박테리움 애니멀리스 락티스 hem20-01 균주, 및 상기 균주 또는 이의 배양물을 포함하는 우울증 치료용 조성물
JP7595342B2 (ja) * 2021-02-03 2024-12-06 高梨乳業株式会社 抗ストレス用組成物
CN113151103B (zh) * 2021-05-14 2022-11-18 山西农业大学 一株具有缓解ⅱ型糖尿病功效的短乳杆菌及其应用
US20250352589A1 (en) * 2021-11-03 2025-11-20 Institut National de la Santé et de la Recherche Médicale Oxytocin-mimetic compositions and uses thereof
EP4176890A1 (en) * 2021-11-03 2023-05-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Oxytocin-mimetic compositions and uses thereof
CN119095607A (zh) 2022-02-25 2024-12-06 Winclove控股有限公司 益生菌组合物在自我报告的精神疲劳的表现、优选低精力水平的表现的治疗方法中的用途
KR102686044B1 (ko) * 2022-04-28 2024-07-19 주식회사 에이치이엠파마 신규한 비피도박테리움 비피덤 hem972 균주, 및 상기 균주 또는 이의 배양물을 포함하는 장내 환경 개선용 조성물
WO2024193579A1 (en) * 2023-03-23 2024-09-26 The Chinese University Of Hong Kong Synbiotic compositions for enhancing and restoring gut epithelial barrier

Also Published As

Publication number Publication date
US20180271919A1 (en) 2018-09-27
KR20170129718A (ko) 2017-11-27
AU2016214420B2 (en) 2021-11-11
ECSP17053244A (es) 2019-03-29
EP3253397A1 (en) 2017-12-13
CN107427539A (zh) 2017-12-01
AU2016214420A1 (en) 2017-08-24
WO2016124642A1 (en) 2016-08-11
CA2975553A1 (en) 2016-08-11

Similar Documents

Publication Publication Date Title
CR20170355A (es) Composición probiótica que comprende al menos bifidobacterium bifidum w23 y es capaz de controlar la función de la barrera intestinal
CL2018000150A1 (es) Compuestos útiles como inmunomoduladores (divisional de solicitud 201600508)
CL2020000422A1 (es) Composiciones de glp-1 y sus usos.
CL2018001621A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)
EP4219713A3 (en) Products and compositions
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
BR112016024850A2 (pt) composições e métodos para modulação da expressão 3 semelhante a antiopoietina
MX2020001555A (es) Preparaciones terapéuticas de glicanos y métodos relacionados con estas.
BR112018003780A2 (pt) composições que compreendem um composto de urolitina
MX2017013142A (es) Terapia combinada para tratar cáncer.
MX2017011037A (es) Bacteria manejada geneticamente para tratar enfermedades que se benefician de inflamacion intestinal reducida y/o barrera mucosa intestinal fortalecida.
MX2019014045A (es) Composiciones y metodos.
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
BR112018003745A2 (pt) composições que compreendem um composto de urolitina
NZ709392A (en) Synergistic bacterial compositions and methods of production and use thereof
MX373187B (es) Terapia de combinación para tratar cáncer.
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
CL2016003212A1 (es) Derivados de indolín-2-ona o pirrolo-piridín-2-ona.
BR112017014107A2 (pt) composição nutricional útil no tratamento de pacientes com ibd
CL2017001335A1 (es) Cápsulas blandas de calcifediol.
MX376700B (es) Compuestos heterociclicos fusionados como moduladores s1p.
MX2018013221A (es) Compuestos de pirazol disustituidos para el tratamiento de enfermedades.
ECSP14014778A (es) Composiciones derivadas de la quitosana
SG11201608730UA (en) Bifidobacterium breve cbt br3 strain for promotion of growth and nutraceutical composition for promotion of growth containing the same
BR112014032764A2 (pt) composição farmacêutica contendo fimasartana e hidroclorotiazida